SOLEUS CAPITAL MANAGEMENT L P
Q3 2025 Form 13-F
GREENWICH, CONNECTICUT
CIK 0001802630
· CRD 294459
· SEC-registered investment adviser
$2.0B Reported Value Total
SOLEUS CAPITAL MANAGEMENT, L.P. reports 14 total accounts under management (AUM). There are 14 discretionary accounts valued at $2,335,377,666, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
14 funds
· $3.8B gross asset value
Hedge Fund: $3.0B · Private Equity Fund: $765.8M
Source: Form ADV filed 2026-04-27
Reported value
$2.0B
Quarter over quarter
+26.8%
Holdings
87
Top-10 concentration
48.1%
Key People
Form ADV owners & control persons
Guy Bezalel Levy
SOLE OWNER
Charles Arthur Davis
MEMBER
Stephen Nmn Friedman
MEMBER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2025 13F record
Q3 2025 13F filing summary
| Period of report | September 30, 2025 |
|---|---|
| Filed | November 14, 2025 |
| Form | 13F-HR |
| Reported value | $2.0B |
| Positions | 87 |
| Change in reported value | +31.5% |
| New positions | 18 |
| Exited positions | 25 |
| Position turnover | 38.4% |
| Top-10 concentration | 48.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 11, 2026
|
97 | $2.9B |
|
Q1 2026 13F
Filed May 14, 2026
|
93 | $2.5B |
|
Q4 2025 13F
Filed Feb 12, 2026
|
94 | $2.7B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
87 | $2.0B |
|
Q2 2025 13F
Filed Aug 15, 2025
|
94 | $1.5B |
|
Q1 2025 13F
Filed May 15, 2025
|
74 | $1.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
80 | $1.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
86 | $1.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
92 | $1.1B |
|
Q1 2024 13F
Filed May 15, 2024
|
90 | $1.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
73 | $901.2M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
90 | $1.1B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
101 | $899.5M |
|
Q1 2023 13F
Filed May 15, 2023
|
76 | $965.7M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
72 | $697.1M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
75 | $736.0M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
70 | $641.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
63 | $775.1M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
65 | $998.8M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
70 | $641.7M |
7 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | KRYS KRYSTAL BIOTECH INC | $179.9M | 9.05% |
| 2 | TGTX TG THERAPEUTICS INC | $138.9M | 6.99% |
| 3 | NVCR NOVOCURE LTD | $124.6M | 6.27% |
| 4 | XBI P SPDR SERIES TRUST | $115.2M | 5.8% |
| 5 | ELV ELEVANCE HEALTH INC FORMERLY | $83.9M | 4.22% |
| 6 | BBNX BETA BIONICS INC | $76.9M | 3.87% |
| 7 | UTHR UNITED THERAPEUTICS CORP DEL | $62.9M | 3.17% |
| 8 | TERN TERNS PHARMACEUTICALS INC | $61.0M | 3.07% |
| 9 | CELC CELCUITY INC | $58.2M | 2.93% |
| 10 | INSP INSPIRE MED SYS INC | $54.0M | 2.72% |
| 11 | TWST TWIST BIOSCIENCE CORP | $52.5M | 2.64% |
| 12 | ARGX ARGENX SE | $51.2M | 2.58% |
| 13 | ORGO ORGANOGENESIS HLDGS INC | $51.2M | 2.58% |
| 14 | BMRN BIOMARIN PHARMACEUTICAL INC | $48.2M | 2.43% |
| 15 | CDTX CIDARA THERAPEUTICS INC | $47.3M | 2.38% |
| 16 | PRAX PRAXIS PRECISION MEDICINES I | $45.5M | 2.29% |
| 17 | FOLD AMICUS THERAPEUTICS INC | $37.0M | 1.86% |
| 18 | INDV INDIVIOR PLC | $35.3M | 1.78% |
| 19 | MDGL MADRIGAL PHARMACEUTICALS INC | $31.3M | 1.58% |
| 20 | ANIP ANI PHARMACEUTICALS INC | $31.2M | 1.57% |
Values as reported on the Q3 2025 Form 13F. Every position is in the holdings table below.